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Abstract
Objectives: To examine the effects of Roux-en-Y gastric bypass (RYGB) surgery with and without laparoscopic removal of
omental fat (omentectomy) on the temporal gene expression profiles of skeletal muscle.
Design: Previously reported were the whole-body metabolic effects of a randomized, single-blinded study in patients
receiving RYGB surgery stratified to receive or not receive omentectomy. In this follow up study we report on changes in
skeletal muscle gene expression in a subset of 21 patients, for whom biopsies were collected preoperatively and at either 6
months or 12 months postoperatively.
Methodology/Principal Findings: RNA isolated from skeletal muscle biopsies of 21 subjects (8 without omentectomy and
13 with omentectomy) taken before RYGB or at 6 and 12 months postoperatively were subjected to gene expression
profiling via Exon 1.0 S/T Array and Taqman Low Density Array. Robust Multichip Analysis and gene enrichment data
analysis revealed 84 genes with at least a 4-fold expression difference after surgery. At 6 and 12 months the RYGB with
omentectomy group displayed a greater reduction in the expression of genes associated with skeletal muscle inflammation
(ANKRD1, CDR1, CH25H, CXCL2, CX3CR1, IL8, LBP, NFIL3, SELE, SOCS3, TNFAIP3, and ZFP36) relative to the RYGB non-
omentectomy group. Expressions of IL6 and CCL2 were decreased at all postoperative time points. There was differential
expression of genes driving protein turnover (IGFN1, FBXW10) in both groups over time and increased expression of PAAF1
in the non-omentectomy group at 12 months. Evidence for the activation of skeletal muscle satellite cells was inferred from
the up-regulation of HOXC10. The elevated post-operative expression of 22 small nucleolar RNAs and the decreased
expression of the transcription factors JUNB, FOS, FOSB, ATF3 MYC, EGR1 as well as the orphan nuclear receptors NR4A1,
NR4A2, NR4A3 suggest dramatic reorganizations at both the cellular and genetic levels.
Conclusions/Significance: These data indicate that RYGB reduces skeletal muscle inflammation, and removal of omental fat
further amplifies this response.
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Introduction
Obesity is an important risk factor for prevalent chronic
health complications, such as type 2 diabetes (T2D) and
cardiovascular disease. At the nexus of obesity-related co-
morbidities is insulin resistance, which is characterized by a
reduced responsiveness of insulin-sensitive tissues such as
skeletal muscle, adipose tissue and liver to insulin-mediated
glucose and lipid metabolism. Insulin resistance in skeletal
muscle is considered especially pathogenic, as this tissue
accounts for the majority of insulin-stimulated glucose disposal
[1]. Accumulation of intramuscular lipid and excess plasma free
fatty acid levels are considered central to aberrant skeletal
muscle insulin signaling [2]. The pro-inflammatory state
associated with obesity [3] is also implicated as a factor in
skeletal muscle insulin resistance [4,5].
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e28577Expanded visceral fat, as opposed to subcutaneous fat, is more
strongly associated with insulin resistance and various comorbid-
ities, especially cardiovascular disease, hypertension and hyperlip-
idemia [6,7,8,9,10]; it is also considered an important source of
systemic free fatty acid (FFA) overload and inflammation due to
enhanced lipolysis, cytokine secretion [11,12], and macrophage
infiltration [13]. Based on the available literature, it is clear that
visceral fat is associated with insulin resistance. Our recent findings
show that removal of the omentum with RYGB does not impart
any additional benefits on hepatic insulin sensitivity or on insulin
induced peripheral (muscle) glucose utilization [14]. However,
these observations do not rule out any beneficial effects of removal
of visceral fat on other muscle-mediated variables that could
influence muscle glucose utilization. Recently, Varma et al.
provided evidence that pro-inflammatory macrophages infiltrate
skeletal muscle of obese, insulin-resistant humans and are activated
Figure 1. CONSORT Diagram.
doi:10.1371/journal.pone.0028577.g001
Table 1. Effect of Roux-en-Y Gastric Bypass surgery with or without omentectomy on body composition and metabolic variables.
Category Before surgery 6 months post-op 12 months post-op P value
Omentectomy (n) No (8) Yes (13) No (7) Yes (12) No (8) Yes (8) Group G6T Time
Gender (F/M) 7/1 11/2 6/1 10/2 7/1 6/2
Ethnicity (Cau/AfAm) 6/2 9/4
Diabetes (N/Y) 2/6 6/7 2/5 5/7 2/6 3/5
Weight (kg) 129622 137617 97616 98613 87616 8968 0.311 0.191 ,0.001
Body mass index (kg/m
2) 46.366.2 49.668.6 34.364.8 34.865.7 31.164.5 31.864.7 0.291 0.174 ,0.001
Fat mass (kg) 62613 62611 42612 40693 3 611 3468 0.924 0.691 ,0.001
Lean mass (kg) 64612 67611 53614 54695 0 611 5268 0.538 0.353 ,0.001
Body fat (%) 48654 7 654 3 674 2 663 8 683 9 67 0.661 0.478 ,0.001
Glucose (mg/dL) 141652 133644 93615 96610 92613 107650 0.601 0.455 ,0.001
Insulin (mU/L) 29614 24612 8 6 58 638 647 64 0.239 0.504 ,0.001
Glycosylated hemoglobin (%) 6.360.7 6.660.8 5.760.8 5.860.5 5.760.5 6.061.4 0.706 0.843 ,0.001
Free fatty acids (mmol/L) 0.6460.12 0.7060.23 0.6560.23 0.6060.15 0.5360.08 0.5860.16 0.731 0.905 0.054
Total triglyceride (mg/dL) 155667 148691 94643 83629 83635 81625 0.723 0.679 ,0.001
Leptin (ng/mL) 36613 35610 20612 16651 7 612 1369 0.701 0.507 ,0.001
Total adiponectin (mg/mL) 7.565.0 8.166.6 9.863.7 11.064.3 18.669.7 13.468.3 0.508 0.096 ,0.001
M (mg/kg?min) 4.461.8 4.861.3 6.962.0 8.661.5 8.961.9 9.562.2 0.287 0.917 ,0.001
M/I (mg?mL/kg?min?mU) 16.069.3 21.1613.9 32.8613.5 35.3613.3 36.8614.5 37.2610.4 0.367 0.595 ,0.001
Values are means 6 SD; P values for the main effects of group and time and their interaction (G6T) are reported. M, glucose disposal rate per kg of body weight; M/I,
insulin sensitivity index (M-value per unit of plasma insulin).
doi:10.1371/journal.pone.0028577.t001
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causative of skeletal muscle insulin resistance. Elevated proin-
flammatory cytokines such as TNF-a as well as increased
proinflammatory pathway activation such as NFkB signaling
through IkB kinase (IKK) and JNK-mediated phosphorylation of
IRS-1 are also observed in various models of obesity induced
insulin resistance [16,17,18,19]. These observations suggest local
inflammation in muscle as a possible mechanism by which the
effects of insulin may be governed.
RYGB surgery results in 40% weight loss and resolution of
T2D in 80% of patients by one year after surgery [20];
additionally, skeletal muscle insulin sensitivity is improved
,two-fold [14,21]. Relatively few studies have examined the
effect of RYGB on muscle lipid content [22,23] and insulin
signaling proteins [24,25]. One study revealed a differential
expression of genes involved in insulin signaling (growth factor
receptor-bound protein 14; GRB14), triglyceride synthesis
(glycerol-3-phosphate dehydrogenase 1; GPD1), and muscle mass
(myostatin; GDF8) by performing microarray analysis on muscle
biopsies from 3 subjects obtained before and 12 months after
gastric bypass surgery [26]. In the current study, we report the
effects of RYGB combined with omental fat removal on skeletal
muscle glucose utilization and on gene expression profiles,
especially those related to the inflammatory pathways. Serial
Figure 2. Box plot depicting the difference among microarray expression datasets (chips) before and after normalization by Robust
Microarray Averaging (RMA). Boxes show the 25th and 75th percentiles in the distribution of log-transformed (log base 2) intensities. The median
is the horizontal bar in the middle of the box. The whiskers (dotted lines extending from the boxes) illustrate the maximum value or 1.5 times the
interquartile range of data (IQR), whichever is smaller. The circles display any points beyond these whiskers.
doi:10.1371/journal.pone.0028577.g002
Table 2. Serological measures of inflammation determined before and after RYGB with and without omentectomy.
Category Before surgery 6 months post-op 12 months post-op P value
Omentectomy No Yes No Yes No Yes Group G6T Time
C-reactive protein (mg/mL) 11.069.1 9.3611.0 2.461.4 3.263.6 2.863.8 1.060.5 0.716 0.983 ,0.001
IL-1b (pg/ml) 2.964.6 18.6638.5 2.261.2 6.2610.5 1.961.4 16.2634.5 0.194 0.119 0.06
IL-6 (pg/ml) 3.162.0 62.56190.5 5.464.7 10.9621.5 4.466.6 62.16159.7 0.299 0.085 0.114
IL-8 (pg/ml) 3.762.1 18.6645.4 3.361.4 8.569.0 3.861.7 19.6638.8 0.265 0.246 0.263
IL-10 (pg/ml) 1.861.0 3.864.4 1.960.9 1.961.1 1.360.5 2.060.7 0.106 0.316 0.089
MCP-1 (pg/ml) 85.9671.1 135.56209.4 70.4666.8 59.8652.9 57.4649.1 97.96175.7 0.087 0.41 0.001
TNF-a (pg/ml) 1.861.7 12.1623.3 1.861.0 4.767.4 1.260.6 9.4615.7 0.123 0.18 0.119
doi:10.1371/journal.pone.0028577.t002
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were performed preoperatively and at 6 and/or 12 months post-
RYGB in 21 obese subjects undergoing RYGB and randomized
to omentectomy.
Materials and Methods
Ethics Statement
All subjects provided written, informed consent before participat-
ing in this study, which was approved by the Health Sciences
Committee of the Vanderbilt University Institutional Review Board.
Subjects
Obese men and women between 18 and 60 years old, with and
without T2D, and with physician’s approval for RYGB, were
recruited from the Center for Surgical Weight Loss at Vanderbilt
University Medical Center (Nashville, TN). The cohorts consisted
of 13 subjects receiving RYGB surgery plus omentectomy (11
women and 2 men, 4468 years old, 7 with T2D) and 8 subjects
receiving RYGB surgery alone (7 women and 1 man, 40611 years
old, 6 with T2D, see Figure 1 and Table 1). Diabetic subjects
using oral anti-diabetic agents were asked to discontinue all
medications for 5 days prior to each study visit.
Study Protocol
We conducted a 12-month randomized, controlled trial wherein
subjects underwent RYGB with or without omentectomy. Studies
were conducted preoperatively and at 6 and 12 months post-
RYGB at the Vanderbilt Clinical Research Center (CRC) between
March 2005 and December 2008. The protocol for this trial and
the CONSORT checklist are available as supporting information
(Protocol S1 and Checklist S1). Randomization was conducted
using a computer generated code with a permuted block size of
four. Separate randomization codes were used for Caucasian
females, Caucasian males, African American females, and African
American males to achieve equal gender and ethnic distributions
in each group. The study coordinator generated the random
allocation sequence and notified the surgeon at the beginning of
the surgical procedure of the patient’s randomization category. All
recruited participants and researchers involved in the conduct of
the study and sample analysis were blinded to treatment. The
primary outcome measure in this study was insulin sensitivity as
measured by the hyperinsulinemic euglycemic clamp [14], and a
secondary outcome measure was gene expression in skeletal
muscle biopsies. Enrollment was concluded when we obtained
sufficient power for the primary outcome measure.
Muscle insulin sensitivity was estimated using a hyperinsulin-
emic euglycemic clamp as the rate of exogenous dextrose (20%)
infusion to maintain euglycemia (plasma glucose of 90–100 mg/
dl) during a high-dose insulin infusion (2–3 mU/kg.min). The
clamp studies were performed in all subjects at three time points:
(a) In the preoperative period, at least one week prior to the
surgical procedure, and at (b) 6-months and (c) 12 months
postoperatively. Muscle biopsies were acquired from the vastus
lateralis muscle using a Bergstrom needle as previously described
[14]. Basal (prior to RYGB) muscle biopsies were obtained from
all subjects (n=21) at the time of the surgical procedure,
immediately after adequate induction of general anesthesia and
prior to initiation of the RYGB procedure. The postoperative
Figure 3. Heat map displaying hierarchical clustering results from microarray expression profile data derived from skeletal muscle
RNA pools. Samples include 0, 6 and 12 months ‘‘No’’ omentectomy and 0, 6 and 12 months ‘‘Yes’’ omentectomy. The expression of 2,697 genes is
represented as a dendrogram after applying filtering criteria for selecting genes with a log2 ratio intensity greater than 1 (ratio.2). Gene expression
ratios are displayed by applying progressively brighter shades of red (down-regulated) or green (up-regulated) to log2 ratios that increasingly deviate
from zero.
doi:10.1371/journal.pone.0028577.g003
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prior to initiation of the insulin clamp, using 1% Lidocaine
solution as local anesthetic. Fourteen subjects had muscle biopsies
at the three specified time points (pre-RYGB and at 6 and 12
months post-RYGB); 5 subjects had muscle biopsies obtained
during the basal period and at 6 months post-RYGB, and 2
subjects had biopsies performed during the basal period and at 12
months post-RYGB. Biopsy specimen were dissected free of fat
and vasculature, blotted free of blood and immediately snap
frozen in liquid nitrogen and stored at 280uC until analyzed.
The surgical procedure consisted of a laparoscopic RYGB
surgery, in which a small gastric pouch (,25 ml) was created
and a Roux-en-Y gastrojejunostomy with a 30- to 50-cm
biliopancreatic limb and a 100- to 200-cm Roux limb was
constructed. In patients randomized to receive an omentectomy,
surgeons resected an average of 0.74 kg of greater omentum [14].
Blood was collected and assays were performed as previously
described [14]. The inflammatory cytokines monocyte chemotac-
tic protein-1 (MCP-1), interleukin (IL)-1b, IL-6, IL-8, IL-10, and
tumor necrosis factor (TNF)-a were measured by multiplex BD
TM
Cytokine Bead Array combined with flow cytometry (BD
Biosciences, San Diego, California). Fat and lean body mass were
assessed with dual-energy x-ray absorptiometry (GE Lunar
Prodigy, Madison, WI) using half-body scans[27].
RNA isolation
Skeletal muscle biopsies were chopped into small pieces at
220uC and 1 ml Trizol (Invitrogen, Carlsbad, CA) was added per
100 mg of sample. RNA was extracted using Qiagen’s RNase-free
DNase Set (Valencia, CA) supplied protocol with the following
modification. RNA was precipitated with 0.25 volumes isopropa-
nol (Fisher Scientific, Fairlawn, NJ) and 0.25 volumes of RNA
precipitation solution (7% NaCl/21% disodium citrate). DNase
treatment was performed by adding 10 ml DNase and 70 ml Buffer
RDD (Qiagen) per 100 ml sample. Trizol isolation was repeated
once or twice to remove the DNase and any remaining fats or
salts. RNA was re-suspended in RNase/DNase free water.RNA
quality was assessed by the Vanderbilt Microarray Shared
Resource on an Agilent 2100 Bioanalyzer utilizing RNA integrity
numbers (RINs), 260/280 absorption and 28 s:18 s ratios [28].
RNA samples included in this experiment exceeded the recom-
mended RIN of 6, with an average RIN of 7.4.
Table 3. Genes changed $4 fold (log 2 base $2) between 6 and 0 months no omentectomy.
Probe ID Gene Symbol Gene Description Process Cytoband mRNA Accession log2fold
7955858 HOXC10 homeobox C10 transcription factor 12q13.3 NM_017409 2.05587
8148317 MYC v-myc myelocytomatosis viral
oncogene homolog
transcription factor 8q24.21 NM_002467 22.0047
8026047 JUNB jun B proto-oncogene transcription factor 19p13.2 NM_002229 22.0214
8029693 FOSB FBJ murine osteosarcoma viral
oncogene homolog B
transcription factor 19q13.32 NM_006732 22.17407
8108370 EGR1 early growth response 1 transcription factor 5q31.1 NM_001964 22.5463
7975779 FOS v-fos FBJ murine osteosarcoma viral
oncogene homolog
transcription factor 14q24.3 NM_005252 23.14739
7981990 PWCR1 Prader-Willi syndrome chromosome region 1 small nucleolar RNA expression 15q11.2 NR_003106 2.53618
7964246 SNORD59B small nucleolar RNA, C/D box 59B small nucleolar RNA expression 12q13.3 NR_003046 2.49785
7982094 SNORD115-44 small nucleolar RNA, C/D box 115-44 small nucleolar RNA expression 15q11.2 NR_003359 2.43735
7948910 SNORD25 small nucleolar RNA, C/D box 25 small nucleolar RNA expression 11q13 NR_002565 2.09656
8012949 FBXW10 F-box and WD repeat domain
containing 10, mRNA
protein turnover 17p12 ENST00000308799 2.30938
7908650 IGFN1 eEF1A2 binding protein protein turnover 1q32.1 NM_178275 22.25232
8090872 KY kyphoscoliosis peptidase other 3q22.2 NM_178554 2.06643
8175311 CXorf48 chromosome X open reading frame
48 transcript variant 2
other Xq26.3 ENST00000344129 22.09328
8156848 NR4A3 nuclear receptor subfamily 4, group A,
member 3
orphan receptor 9q22 NM_173198 22.75007
8085972 GADL1 glutamate decarboxylase-like 1 insulin signaling 3p24.1-p23 NM_207359 2.26062
7921690 ITLN1 intelectin 1 (galactofuranose binding)
(omentin-1)
insulin signaling 1q22-q23.5 NM_017625 22.40258
8172204 MAOB monoamine oxidase B inflammation Xp11.23 NM_000898 2.08435
8131803 IL6 interleukin 6 (interferon, beta 2) inflammation 7p21 NM_000600 22.27324
8006433 CCL2 chemokine (C-C motif) ligand 2 (MCP-1) inflammation 17q11.2-q12 NM_002982 22.3367
8175531 CDR1 cerebellar degeneration-related
protein 1, 34kDa
inflammation Xq27.1-q27.2 NM_004065 22.51038
7934979 ANKRD1 ankyrin repeat domain 1 (cardiac muscle) inflammation 10q23.31 NM_014391 23.16087
7982597 THBS1 thrombospondin 1 extracellular matrix protein 15q15 NM_003246 22.11267
8106573 THBS4 thrombospondin 4 extracellular matrix protein 5q13 NM_003248 22.23557
7902687 CYR61 cysteine-rich, angiogenic inducer, 61 extracellular matrix protein 1p31-p22 NM_001554 22.78682
doi:10.1371/journal.pone.0028577.t003
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Probe ID Gene Symbol Gene Description Process Cytoband mRNA Accession log2fold
7908650 IGFN1 eEF1A2 binding protein protein turnover 1q32.1 NM_178275 22.55556
8012949 FBXW10 F-box and WD repeat domain
containing 10
protein turnover 17p12 ENST00000308799 2.06496
7942476 PAAF1 proteasomal ATPase-associated factor 1 protein turnover 11q13.4 NM_025155 2.01504
7921690 ITLN1 intelectin 1 (galactofuranose
binding) (omentin -1)
insulin signaling 1q22-q23.5 NM_017625 22.23682
8108370 EGR1 early growth response 1 transcription factor 5q31.1 NM_001964 23.05413
7975779 FOS v-fos FBJ murine osteosarcoma viral
oncogene homolog
transcription factor 14q24.3 NM_005252 24.09474
8029693 FOSB FBJ murine osteosarcoma viral
oncogene homolog B
transcription factor 19q13.32 NM_006732 22.12644
8026047 JUNB jun B proto-oncogene transcription factor 19p13.2 NM_002229 22.38627
8148317 MYC v-myc myelocytomatosis viral
oncogene homolog
transcription factor 8q24.21 NM_002467 22.0096
7955858 HOXC10 homeobox C10 transcription factor 12q13.3 NM_017409 2.0778
8006433 CCL2 chemokine (C-C motif) ligand 2 inflammation 17q11.2-q12 NM_002982 22.09334
8175531 CDR1 cerebellar degeneration-related
protein 1, 34kDa
inflammation Xq27.1-q27.2 NM_004065 23.36346
8086344 CX3CR1 chemokine (C-X3-C motif) receptor 1 inflammation 3p21|3p21.3 NM_001337 2.12768
8131803 IL6 interleukin 6 (interferon, beta 2) inflammation 7p21 NM_000600 22.57781
8156848 NR4A3 nuclear receptor subfamily 4,
group A, member 3
orphan receptor 9q22 NM_173198 22.72922
7899480 SNORA73A small nucleolar RNA, H/ACA box 73A small nucleolar RNA
expression
1p36.1 NR_002907 2.48545
7982038 SNORD115-1 small nucleolar RNA, C/D box 115-1 small nucleolar RNA
expression
15q11.2 NR_001291 2.68633
7982078 SNORD115-11 small nucleolar RNA, C/D box 115-11 small nucleolar RNA
expression
15q11.2 NR_003303 2.45315
7982024 SNORD115-12 small nucleolar RNA, C/D box 115-12 small nucleolar RNA
expression
15q11.2 NR_003304 2.54694
7982050 SNORD115-12 small nucleolar RNA, C/D box 115-12 small nucleolar RNA
expression
15q11.2 NR_003304 2.53634
7982084 SNORD115-12 small nucleolar RNA, C/D box 115-12 small nucleolar RNA
expression
15q11.2 NR_003304 2.03653
7982008 SNORD115-13 small nucleolar RNA, C/D box 115-13 small nucleolar RNA
expression
15q11.2 NR_003305 2.68633
7982032 SNORD115-16 small nucleolar RNA, C/D box 115-16 small nucleolar RNA
expression
15q11.2 NR_003308 2.68633
7982046 SNORD115-20 small nucleolar RNA, C/D box 115-20 small nucleolar RNA
expression
15q11.2 NR_003312 2.56052
7982052 SNORD115-23 small nucleolar RNA, C/D box 115-23 small nucleolar RNA
expression
15q11.2 NR_003315 3.03821
7982056 SNORD115-25 small nucleolar RNA, C/D box 115-25 small nucleolar RNA
expression
15q11.2 NR_003342 2.77049
7982058 SNORD115-26 small nucleolar RNA, C/D box 115-26 small nucleolar RNA
expression
15q11.2 NR_003343 2.46435
7982028 SNORD115-43 small nucleolar RNA, C/D box 115-43 small nucleolar RNA
expression
15q11.2 NR_003358 2.45315
7982094 SNORD115-44 small nucleolar RNA, C/D box 115-44 small nucleolar RNA
expression
15q11.2 NR_003359 2.75753
7982016 SNORD115-5 small nucleolar RNA, C/D box 115-5 small nucleolar RNA
expression
15q11.2 NR_003297 2.54694
7982018 SNORD115-6 small nucleolar RNA, C/D box 115-6 small nucleolar RNA
expression
15q11.2 NR_003298 2.30491
7982090 SNORD115-6 small nucleolar RNA, C/D box 115-6 small nucleolar RNA
expression
15q11.2 NR_003298 2.27704
7982020 SNORD115-7 small nucleolar RNA, C/D box 115-7 small nucleolar RNA
expression
15q11.2 NR_003299 3.00484
7982092 SNORD115-9 small nucleolar RNA, C/D box 115-9 small nucleolar RNA
expression
15q11.2 NR_003301 2.45315
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To minimize costs, initial gene expression profiles of muscle RNA
pools were determined using Affymetrix GeneChip Human Exon
1.0 ST arrays. Skeletal muscle RNA pools (pre-RYGB, 6 months
post-op, and 12-months post-op) from RYGB subjects with and
without omentectomy (6pools total)were prepared from 42 different
skeletal muscle RNA samples. RNA samples were prepared for
microarray analysis using the standard Affymetrix protocol (Affyme-
trixInc.,Santa Clara,CA)and published techniques[29,30].Briefly,
200 ngpooled totalRNA and poly-A spike incontrols,were brought
to 5 ml with nuclease free water. First Strand Synthesis Master mix
was added to the sample mix and incubated at 42uCf o r1h r ;
enzymes were heat inactivated 10 minutes at 70uC, followed by a
cooling to 4uC for 2 minutes. Subsequently, second strand synthesis
master mix was added to the sample mix and incubated at 16uCf o r
2 hours. The reactions were heat-inactivated by 10 minute
incubation at 75uC. The resulting cDNA was then processed in an
IVT reaction to generate cRNA that was used in first strand
synthesis reactions to generate targets of the correct sense for
hybridization to the Affymetrix Exon arrays. The reactions were set
up with 10 mg cRNA, random hexamer, and first strand synthesis
reagents to make cDNA. The targets were then treated with RNAse
to remove template RNA and cleaned up over kit supplied columns,
orAgencourtSPRI beads,followingmanufacturer’sprotocol.Atotal
of 5.5 mg of the clean cDNA target was then enzymatically
fragmented and end-labeled using the Affymetrix kit reagents. The
cRNA, cDNA, and fragmented and end-labeled targets were
assessed by Agilent bioanalysis to ensure that the amplified targets
met the recommended smear range, and that fragmentation and
end-labeling were complete.
Microarray Hybridization
The requisite amount of target was then added to hybridization
cocktail to give a final target concentration of ,25 ng/mli nt h e
hybridization cocktail. The targets in hybridization cocktail were heat
denatured at 99uC for 5 minutes, cooled to 45uCf o r5m i n u t e s ,
centrifuged and then loaded on the Affymetrix cartridge arrays for a
hybridization period of 16 hours at 45uC, with rotation of 60RPM in
the Affymetrix Model 645 Hybridization Oven. The cartridge arrays
were washed, and stained per standard Affymetrix Protocols using
Affymetrix Hybridization Wash and Stain kit reagents. After washing
and staining, the arrays were scanned in an Affymetrix 7G plus
scanner. The resulting data was acquired by GCOS software.
Validation by Taqman Low Density Array
To validate the expression levels of probes from RNA analyses,
the 42 individual RNA samples comprising the pool were analyzed
using Taqman Low Density Array (TLDA) [31]. An additional 12
skeletal muscle RNA samples not previously analyzed by micro-
array (baseline and post-RYGB in seven additional subjects) also
were included. Total RNA (500 ng) was reverse transcribed to ds
cDNA using random primers, SuperScript II Reverse Transcriptase
(Invitrogen, Carlsbad, CA) according to the supplied protocol.
Following reverse transcription, each 20 ml reaction was diluted
with25 ml ofDNase/RNase-freewater.QuantitativePCRwas then
performed using 500 ng of cDNA per reaction well. Thirty-one
experimental genes and one control gene were assayed by qPCR.
Thirty-two gene specific assays were purchased from Applied
Biosystems (Foster City, CA) as custom TLDA microfluidics cards
(Format 32) with TLDA probes (Table S3) spotted in triplicate on
384 well plates. All reactions were carried out at the following
thermocycling conditions: Step 1: 10 min at 95uC, Step 2: 40 cycles
of 15 s at 95uC, and Step 3: 1 min at 60uC. An Applied Biosystems
ABI 7900HT unit with automation attachment (Foster City, CA)
was used for real-time PCR. This unit is capable of collecting
spectral data at multiple points during a PCR run.
Statistical Quality Control, Methods and Bioinformatics
The sample size for the current study was dictated by availability
of a baseline and at least one postoperative muscle biopsy collected
from the parent study[14].Thestudypoweranalysiswascompleted
using the general linear model. A sample size of at least 7 patients
per condition per time point, provided at least 90% power to detect
an effect size of 4, i.e., 4-fold change, with two-sided false discovery
rate (FDR) of 0.05.
Anthropometric and metabolic parameters were analyzed for an
effect of time and group (omentectomy) using linear mixed effects
models in IBM SPSS version 18 (Chicago, IL). The overall
intensities of all probes across the six microarrays were subjected to
box plot analysis (Figure 2). ExonST 1.0 array data pre-processing
was done using GeneSpring v7.3 software (Agilent Technologies,
Foster City, CA). Probe-level analysis was performed using the
Robust Multichip Analysis (RMA) method [32], but the default
quantile across-sample normalization method of RMA was not
done in order to avoid over-correction for the small sample size.
The expression values were in log2 format after RMA. The change
Probe ID Gene Symbol Gene Description Process Cytoband mRNA Accession log2fold
7948902 SNORD29 small nucleolar RNA, C/D box 29 small nucleolar RNA
expression
11q13 NR_002559 2.34649
7922410 SNORD44 small nucleolar RNA, C/D box 44 small nucleolar RNA
expression
1q25.1 NR_002750 2.10829
8150877 SNORD54 small nucleolar RNA, C/D box 54 small nucleolar RNA
expression
8q12 NR_002437 2.06555
7902687 CYR61 cysteine-rich, angiogenic inducer, 61 extracellular matrix 1p31-p22 NM_001554 22.6069
8106573 THBS4 thrombospondin 4 extracellular matrix 5q13 NM_003248 22.07002
8042788 ACTG2 actin, gamma 2, smooth muscle, enteric other 2p13.1 NM_001615 22.1841
7931832 AKR1C2 aldo-keto reductase family 1, member C2 other 10p15-p14 NM_205845 2.20199
7924821 gm127 similar to RIKEN 2610020C11 other 1q42.13 AF387613 22.183
8048014 RPE ribulose-5-phosphate-3-epimerase other 2q32-q33.3 NM_199229 2.17662
doi:10.1371/journal.pone.0028577.t004
Table 4. Cont.
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Probe ID Gene Symbol Gene Description Process Cytoband mRNA Accession log2fold
7908650 IGFN1 eEF1A2 binding protein protein turnover 1q32.1 NM_178275 23.10661
8108370 EGR1 early growth response 1 transcription factor 5q31.1 NM_001964 24.47459
7975779 FOS v-fos FBJ murine osteosarcoma viral
oncogene homolog
transcription factor 14q24.3 NM_005252 25.12292
8029693 FOSB FBJ murine osteosarcoma viral
oncogene homolog B
transcription factor 19q13.32 NM_006732 22.78581
8026047 JUNB jun B proto-oncogene transcription factor 19p13.2 NM_002229 23.56001
8148317 MYC v-myc myelocytomatosis viral
oncogene homolog (avian)
transcription factor 8q24.21 NM_002467 23.08841
7909610 ATF3 activating transcription factor 3 transcription factor 1q32.3 NM_001040619 22.23226
8084710 ADIPOQ adiponectin, C1Q and collagen domain
containing
insulin signaling 3q27 NM_004797 22.25931
7960865 SLC2A3 solute carrier family 2 (facilitated glucose
transporter), 3
insulin signaling 12p13.3 NM_006931 22.60975
7934979 ANKRD1 ankyrin repeat domain 1 (cardiac muscle) inflammation 10q23.31 NM_014391 22.57698
8006433 CCL2 chemokine (C-C motif) ligand 2 (MCP-1) inflammation 17q11.2-q12 NM_002982 23.85999
7934916 CH25H cholesterol 25-hydroxylase inflammation 10q23 NM_003956 22.56701
8100994 CXCL2 chemokine (C-X-C motif) ligand 2 (MIP-2a) inflammation 4q21 NM_002089 22.61796
8131803 IL6 interleukin 6 (interferon, beta 2) inflammation 7p21 NM_000600 25.01826
8018864 SOCS3 suppressor of cytokine signaling 3 inflammation 17q25.3 NM_003955 23.40317
8095680 IL8 interleukin 8 inflammation 4q13-q21 NM_000584 22.02015
8062461 LBP lipopolysaccharide binding protein inflammation 20q11.23-q12 NM_004139 22.16848
8162276 NFIL3 nuclear factor, interleukin 3 regulated inflammation 9q22 NM_005384 22.63846
7922229 SELE selectin E (endothelial adhesion molecule 1) inflammation 1q22-q25 NM_000450 22.46165
8122265 TNFAIP3 tumor necrosis factor, alpha-induced protein 3 inflammation 6q23 NM_006290 22.0769
8028652 ZFP36 zinc finger protein 36, C3H type,
homolog (mouse)
inflammation 19q13.1 NM_003407 22.36152
7955589 NR4A1 nuclear receptor subfamily 4, group A,
member 1
orphan receptor 12q13 NM_002135 22.36834
8055952 NR4A2 nuclear receptor subfamily 4, group A,
member 2
orphan receptor 2q22-q23 NM_006186 22.11225
8156848 NR4A3 nuclear receptor subfamily 4, group A,
member 3
orphan receptor 9q22 NM_173198 23.65489
7929816 SCD stearoyl-CoA desaturase (delta-9-desaturase) fatty acid metabolism 10q23-q24 NM_005063 22.69181
7920873 SNORA42 small nucleolar RNA, H/ACA box 42 small nucleolar RNA
expression
1q22 NR_002974 22.13869
8069676 ADAMTS1 ADAM metallopeptidase
w/thrombospondin type 1 motif, 1
extracellular matrix protein 21q21.2 NM_006988 22.77417
7921821 ADAMTS4 ADAM metallopeptidase
w/thrombospondin type 1 motif, 4
extracellular matrix protein 1q21-q23 NM_005099 22.82585
7902687 CYR61 cysteine-rich, angiogenic inducer, 61 extracellular matrix protein 1p31-p22 NM_001554 22.94737
8025601 ICAM1 intercellular adhesion molecule 1 (CD54) extracellular matrix protein 19p13.3-p13.2 NM_000201 22.25818
8065353 THBD thrombomodulin extracellular matrix protein 20p11.2 NM_000361 22.80578
7982597 THBS1 thrombospondin 1 extracellular matrix protein 15q15 NM_003246 23.01553
8152297 ANGPT1 angiopoietin 1 other 8q22.3-q23 NM_001146 2.01173
8176276 ATRX alpha thalassemia/mental retardation
syndrome X-linked
other Xq13.1-q21.1 NM_138270 2.62294
8086330 AXUD1 AXIN1 up-regulated 1 other 3p22 NM_033027 22.06593
8119088 CDKN1A cyclin-dependent kinase inhibitor 1A
(p21, Cip1)
other 6p21.2 NM_078467 22.02657
7971653 DLEU2 deleted in lymphocytic leukemia, 2 other 13q14.3 NR_002612 2.22215
8024485 GADD45B growth arrest and
DNA-damage-inducible, beta
other 19p13.3 NM_015675 22.811
7954090 EMP1 epithelial membrane protein 1 other 12p12.3 NM_001423 22.17339
7995806 MT1A metallothionein 1A antioxidant 16q13 AY028617 22.5602
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expression values. Winner probes for each comparison were
selected based on two stringency criteria: a cutoff of 2 fold (2,697
genes, used for global pathway analysis; Table S1) or 4-fold change
(103 genes, subset selected for TLDA validation; Table S2).
Relative quantitation and standard deviation calculations with
TLDA data were performed by the comparative CT method [33].
The 56 cDNA samples were assayed in triplicate for each gene of
interest and the control. For each gene in each sample, the average
CT and the standard deviation were calculated, and the 18S control
average CT was subtracted from the gene average CT. The resulting
value is the DCT. The standard deviation for the DCT was calculated
by taking the square root of the sum of the control and gene
standard deviations. For comparisons to basal time points, the
average DCT for the basal period pools was subtracted from the
respective average DCT of the 6 and 12 months samples generating
a DDCT. Fold changes between conditions are given by applying the
expression 2
2DDCT, and DDCT 6 standard deviation applied to this
expression gives the range. Correlation analysis was implemented
using the ‘‘stat’’ package under R2.12.1 [34] without adjustment for
multiple comparisons.
Results
Participant Flow, Recruitment, and Numbers Analyzed
Fifty-six of 300 screened subjects were enrolled in the trial
(Figure 1). Twenty-one subjects completed all study components
at all time points (pre-surgery, 6 and 12 month post-operative) and
yielded a complement of muscle RNA samples of sufficient quality
(average RIN of 7.4) to have expression analysis performed. The
first participant was enrolled in March, 2005.
Anthropometric and Metabolic Parameters
Both the omentectomy and non-omentectomy groups exhibited
significant decreases in body weight, BMI, fat mass, and lean mass
during the 12 months after RYGB; there was neither a group effect
nor a group6time interaction (Table 1). Amount of initial weight
lost was 2863% in the first 6 months and 3466% in 12 months
following surgery across both groups. Similarly, fasting levels of
glucose, insulin, triglycerides, leptin, and adiponectin were signifi-
cantly decreased and free fatty acids were marginally decreased over
time without a group or group6time effect. Insulin-stimulated
glucose uptake in the muscle was significantly increased ,2-fold by
12 months after RYGB in both groups, without significant
differences between groups or group6time interactions.
Circulating Inflammatory Markers
A main effect of time post-RYGB was detected for systemic
concentrations of CRP and MCP-1 but not for IL-1b, IL-6, IL-8,
IL-10, nor TNF-a. There was no effect of omentectomy or
group6time interaction for any inflammatory cytokine (Table 2).
Overview of skeletal muscle gene expression patterns
after RYGB with and without omentectomy
We compared skeletal muscle gene expression patterns between
two surgical groups (RYGB surgery with no omentectomy vs.
RYGB surgery with omentectomy) over time (6 vs. 0 months, and
12 vs. 0 months) in six skeletal muscle RNA sample pools derived
by combining equal amounts of RNA from 7 subjects at each time
point. For each time point, the observed gene expression value was
compared to an overall average expression value derived from the
union of all probe intensities (33,297) across all six Affymetrix
Human Exon 1.0 ST Arrays. Probe intensities were then log2
transformed, and those genes expressed greater than 2 fold
(log1=4 fold) within any time-point comparison were collated. In
this manner, not all genes expressed were changed greater than 2-
fold among all time-points. Expression levels of the 2,697 probes in
each of the 6 microarrays changed greater than 2 fold after
hierarchical clustering analysis is displayed graphically in Figure 3
and individual expression values are listed in Table S2. While
significance cannot be derived from these microarray hybridiza-
tions without experimental replication, general expression were
noted. For example, groups without (No) and with (Yes)
omentectomy displayed similar expression profiles at 0 months.
Additionally, most genes downregulated at 0 month were
upregulated at 6 months, and conversely most genes upregulated
at 0 month were downregulated at 6 months. At 12 months in
both the omentectomy and non-omentectomy groups, the overall
abundance of genes changing more than 2-fold was diminished,
with no apparent differences as a function of omentectomy.
Skeletal muscle gene expression changes without
omentectomy
To identify those genes with the greatest change in expression
after RYGB we compared genes with greater than 2-fold (log2)
changes in expression. Table 3 lists those 25 genes that were
differentially expressed comparing 6 vs. 0 months without
omentectomy. The AP-1 transcription factors such as FOS,
FOSB, JUNB as well as MYC and EGR1 were among those
downregulated to the greatest degree at 6 months. These are
immediate early genes acting on a specific biological response that
directly induces or controls a variety of other genes [35].
HOXC10, a gene associated with muscle satellite cell activation,
was the only transcription factor that was upregulated [36]. Genes
regulating various cellular processes averaged a greater than 5-fold
downregulation: inflammation (ANKRD1, CDR1, CCL2, IL6,
MAOB, GADL1, ITLN1); protein turnover (IGFN1, FBXW10);
and extracellular matrix remodeling (CYR61, THBS1, THBS4). The
Probe ID Gene Symbol Gene Description Process Cytoband mRNA Accession log2fold
7995787 MT1M metallothionein 1M antioxidant 16q13 NM_176870 22.49124
7903171 RWDD3 RWD domain containing 3 other 1p21.3 NM_015485 2.03845
8135069 SERPINE1 other 7q21.3-q22 NM_000602 22.67627
8070665 SNF1LK SNF1-like kinase other 21q22.3 NM_173354 22.38371
8100076 YIPF7 Yip1 domain family, member 7 other 4p13 NM_182592 2.07083
8036813 ZNF780B zinc finger protein 780B other 19q13.2 NM_001005851 2.1765
doi:10.1371/journal.pone.0028577.t005
Table 5. Cont.
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SNORD25, and SNORD59B were among those genes which
were upregulated at 6 months without omentectomy.
Table 4 lists the 36 genes that were most changed at 12 vs. 0
months in the RYGB without omentectomy cohort underscoring
thedurabilityoftheseresponses.Severalofthegenesdownregulated
at 6 vs. 0 months without omentectomy also were observed at this
time point, including the AP-1 transcription factors, markers of
satellite cell activation, genes facilitating the inflammatory response,
(CCL2, CDR1, and IL6), and the orphan receptor NR4A3, as well
as genes regulating extracellular matrix formation and protein
turnover. Additionally, over 20 genes regulating small nucleolar
RNA (snoRNA) expression, mostly from the C/D box 115 group,
were upregulated. SnoRNAs are not transcribed into protein
Table 6. Genes changed $4 fold (log 2 base $2) between 12 and 0 months with omentectomy.
Probe ID Gene Symbol Gene Description Process Cytoband mRNA Accession log2fold
7908650 IGFN1 eEF1A2 binding protein protein turnover 1q32.1 NM_178275 22.33443
8108370 EGR1 early growth response 1 transcription factor 5q31.1 NM_001964 24.20485
7975779 FOS v-fos FBJ murine osteosarcoma viral oncogene
homolog
transcription factor 14q24.3 NM_005252 25.064
8029693 FOSB FBJ murine osteosarcoma viral oncogene homolog B transcription factor 19q13.32 NM_006732 22.66602
8026047 JUNB jun B proto-oncogene transcription factor 19p13.2 NM_002229 23.42952
8148317 MYC v-myc myelocytomatosis viral oncogene
homolog (avian)
transcription factor 8q24.21 NM_002467 23.13093
7955858 HOXC10 homeobox C10 transcription factor 12q13.3 NM_017409 2.15884
7902687 CYR61 cysteine-rich, angiogenic inducer, 61 insulin signaling 1p31-p22 NM_001554 22.51451
8163002 KLF4 Kruppel-like factor 4 (gut) insulin signaling 9q31 NM_004235 22.04104
7960865 SLC2A3 solute carrier family 2 (facilitated glucose
transporter) member3
insulin signaling 12p13.3 NM_006931 22.51532
7934979 ANKRD1 ankyrin repeat domain 1 (cardiac muscle) inflammation 10q23.31 NM_014391 23.4932
8006433 CCL2 chemokine (C-C motif) ligand 2 inflammation 17q11.2-q12 NM_002982 23.21861
7934916 CH25H cholesterol 25-hydroxylase inflammation 10q23 NM_003956 22.42635
8100994 CXCL2 chemokine (C-X-C motif) ligand 2 inflammation 4q21 NM_002089 22.2466
8162276 NFIL3 nuclear factor, interleukin 3 regulated inflammation 9q22 NM_005384 22.47028
7922229 SELE selectin E (endothelial adhesion molecule 1) inflammation 1q22-q25 NM_000450 22.42547
8018864 SOCS3 suppressor of cytokine signaling 3 inflammation 17q25.3 NM_003955 23.36272
8122265 TNFAIP3 tumor necrosis factor, alpha-induced protein 3 inflammation 6q23 NM_006290 22.15921
8028652 ZFP36 zinc finger protein 36, C3H type, homolog
(mouse)
inflammation 19q13.1 NM_003407 22.21499
8131803 IL6 interleukin 6 (interferon, beta 2) inflammation 7p21 NM_000600 25.07812
8062461 LBP lipopolysaccharide binding protein inflammation 20q11.23-q12 NM_004139 22.13523
8025828 LDLR low density lipoprotein receptor (familial
hypercholesterolemia)
receptors 19p13.3 NM_000527 22.22451
7955589 NR4A1 nuclear receptor subfamily 4, group A, member 1 receptors 12q13 NM_002135 22.04616
8156848 NR4A3 nuclear receptor subfamily 4, group A, member 3 receptors 9q22 NM_173198 23.6856
8069676 ADAMTS1 ADAM metallopeptidase with thrombospondin
type 1 motif, 1
extracellular matrix 21q21.2 NM_006988 23.41834
7921821 ADAMTS4 ADAM metallopeptidase with thrombospondin
type 1 motif, 4
extracellular matrix 1q21-q23 NM_005099 22.4919
8065353 THBD thrombomodulin extracellular matrix 20p11.2 NM_000361 22.61527
7982597 THBS1 thrombospondin 1 extracellular matrix 15q15 NM_003246 23.12862
8086330 AXUD1 AXIN1 up-regulated 1 other 3p22 NM_033027 22.08176
8084206 B3GNT5 UDP-GlcNAc:betaGal b-1,3-N-
acetylglucosaminyltransferase 5
other 3q28 NM_032047 22.25232
7954090 EMP1 epithelial membrane protein 1 other 12p12.3 NM_001423 22.14602
8024485 GADD45B growth arrest and DNA-damage-inducible, beta other 19p13.3 NM_015675 22.47919
8086538 LOC644714 hypothetical protein LOC644714 other 3p21.31 BC047037 22.13574
7995806 MT1A metallothionein 1A other 16q13 AY028617 22.47681
7995787 MT1M metallothionein 1M other 16q13 NM_176870 22.24145
8135069 SERPINE1 serpin peptidase inhibitor, E1 (plasminogen
activator inhibitor type 1)
other 7q21.3-q22 NM_000602 22.56719
doi:10.1371/journal.pone.0028577.t006
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encoded proteins. Eighteen microarray probes mapping to fifteen
SNORD 115 transcripts derived from cytoband 15q11.2 were
upregulated, as were SNORD29, SNORD44, SNORD54 and
SNORA73A (from the H/ACA group of snoRNAs).
Skeletal muscle gene expression changes with
omentectomy
At 6 vs. 0 months in the RYGB with omentectomy group, the
number of genes differentially expressed in muscle was nearly
double that observed in the RYGB without omentectomy cohort
at the same time point. Table 5 lists the 46 genes that expressed
greater than a 4-fold change. Genes known to be involved in
facilitating the inflammatory response were particularly respon-
sive. In addition to ANKRD1, CCL2, and IL6 observed as being
greater than 4-fold downregulated in the RYGB without
omentectomy group, the inflammatory genes CH25H, CXCL2,
SOCS3, IL8, LBP, NFIL3, SELE and TNFAIP3 also were
downregulated. All of the transcription factors differentially
expressed at 6 months in the non-omentectomy group were also
downregulated in the 6 months with omentectomy group, as was
ATF3. Adiponectin (ADIPOQ) and the glucose transporter
(SLC2A3) genes along with the extracellular matrix proteins
ADAM metallopeptidase 1 and 4 (ADAMTS1 and ADAMTS4),
CYR61, CD54, THBD and THBS1 were all downregulated;
however a handful of genes with varied functions (ATRX,
DLEU2, ZNF780B, YIPF7, RWDD3, ANGPT1) were upregu-
lated. All 3 members of the nuclear orphan nuclear receptor
family 4 (NRFA1-3) recently identified as controlling skeletal
muscle metabolism [37,38] were downregulated; in particular
NR4A3 which was downregulated over 12 fold. Similar
phenomena were observed in the 12 vs. 0 months with
omentectomy group as were found at 6 vs. 0 months with
omentectomy group. A subset of other proteins with varying
functions complete the list of genes with differential expression
values greater than 4 fold; in total 36 genes were observed
(Table 6).
Effects of omentectomy evaluated by global pathway
analysis
To identify pathways in skeletal muscle that were regulated by
RYGB with and without omentectomy we performed two
complimentary analyses. For these analyses those genes detected
as being changed greater than 2-fold (2,697 genes; Table S1)
were analyzed. First, the gene list was analyzed by the
FuncAssociate Gene Ontology program (http://llama.mshri.on.
ca/funcassociate/) to statistically identify overrepresented gene
categories [39]. Cadmium ion binding (GO:0046870), positive
regulation of leukocyte binding (GO:0002687) and cellular
macromolecule catabolic processes (GO:0044265) were top
Figure 4. Bar graph illustrating the fold change of individual genes at 6 vs. 0 months without omentectomy as determined by
microarray (grey) and TLDA profiling (black).
doi:10.1371/journal.pone.0028577.g004
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wiring diagrams of molecular interactions, reactions, and
relations maintained at the Kyoto Encyclopedia of Genes and
Genomes (KEGG) PATHWAY Database. As reported in Table
S4, coverage of 201 pathways by our experimental datasets
revealed that metabolic pathways, cytokine-cytokine receptor interaction,
MAPK signaling pathways, chemokine signaling pathways, and spliceosome
were top ranked.
Validation of microarray expression profiles with TLDA
As the significance of gene expression changes determined with
microarray could not be determined empirically due to the low
number of array replicates, and because a single outlier sample
within an RNA pool could in theory skew results, we elected to
validate the expression changes of select genes in each of the
individual RNA samples comprising the RNA pools using
Taqman Low Density Arrays (TLDA). In addition to the RNA
samples used to prepare the RNA pools, we also included RNA
samples prepared from additional participants lacking a single
study (either 6 or 12 months) time point RNA sample. Using a spot
checking strategy, expression of 31 genes was used to validate
differential expression data discovered during the microarray study
(Table S2). This approach is admittedly restrictive; however, we
focused on genes involved in pathways such as inflammation,
transcriptional regulation, protein turnover and insulin signaling
[40,41]. Gene selection was guided based on literature reviews of
the effects of weight loss on skeletal muscle, our recent report that
omentectomy concurrent with RYGB did not improve muscle
insulin sensitivity [14], and recent observations that altered
intramuscular lipid metabolism, circulating cytokines and macro-
phage infiltration may act synergistically to coordinate insulin
sensitivity [40,41].
Figures 4–7 show the relative average differential expression
values determined by microarray (light grey) and TLDA (dark
grey) for 31 genes, normalized to an 18S RNA control, when
analyzed in triplicate at 0, 6 and 12 months. Of the 5,184 Taqman
analyses performed to validate select microarray-derived expres-
sion values, only 3 reactions did not amplify. In general, there was
good directional (increased or decreased) concordance between
expression values derived from analysis of pooled RNA samples
and the average of each RNA sample analyzed independently. In
most instances, fold expression change values determined by exon
array in pooled RNA samples were greater than the averages of
individual expression values obtained by TLDA (e.g. FOSB, EGR
and IL6 in Figures 4–7). We examined the relationship between
gene expression values revealed by exon array and TLDA
profiling. In all group comparisons, there were strong positive
relationships: 1) 6 vs. 0 months without omentectomy rho=0.559
(Figure 8A); 12 vs. 0 months without omentectomy rho=0.720
(Figure 8B); 6 vs. 0 months with omentectomy rho=0.646
(Figure 8C); and 12 vs. 0 months with omentectomy rho=0.640
(Figure 8D).
Figure 5. Bar graph illustrating the fold change of individual genes at 12 vs. 0 months without omentectomy as determined by
microarray (grey) and TLDA profiling (black).
doi:10.1371/journal.pone.0028577.g005
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This is the first high-throughput study to explore the temporal
changes in human skeletal muscle gene expression after weight loss
through RYGB surgery with tandem laparoscopic omentectomy.
In addition, randomization of subjects to removal of the omentum
at the time of RYGB allowed us to explore the interplay between
visceral adipose and skeletal muscle. While the effects of bariatric
surgery on gene expression in muscle have been reported for a few
targets [42,43,44,45], the influence of the omentum (visceral
adipose) on global skeletal muscle phenotypes (such as insulin
resistance) has been understudied. Visceral adipose is the source of
14–20% of the total FFAs delivered to skeletal muscle in obese
individuals [46,47] and numerous studies have linked circulating
FFA levels and muscle triglyceride accumulation with peripheral
insulin sensitivity [48,49,50,51]. Visceral adipose tissue is also the
site of production of several cytokines thought to initiate and
maintain pro-inflammatory states both locally and in other tissues
[52]. Infiltration and local activation of macrophages in skeletal
muscle also has been described [40,41]. Our group recently
reported, in the same subjects examined in the present study, that
laparoscopic removal of the greater omentum at the time of
RYGB did not significantly enhance weight loss-induced improve-
ments in peripheral insulin sensitivity beyond those observed with
RYGB alone [14]. These findings were unanticipated in light of
the numerous studies associating increased visceral adiposity with
insulin resistance and T2D [53,54,55]. Despite these findings, it
remained possible that omentectomy produced local changes at
the level of the muscle that may not be totally reflected with
associated improvements in peripheral glucose utilization. The
Affymetrix Exon arrays and TLDA approaches utilized in this
study provided a robust and reproducible technique for quanti-
fying gene expression in thousands of independent genes
concurrently in RNA samples isolated from multiple tissue
samples. This approach represents a significant advance in
multivariate gene analysis that was less time- and labor-intensive
than individually analyzing single genes by quantitative RT-PCR.
Our major finding was a broad-based downregulation of
inflammatory-related pathways in skeletal muscle after RYGB
surgery. This response was amplified in the cohort receiving
omentectomy, as evidenced by a greater number of genes with at
least a 4-fold decrease at 6 or 12 months (at least 4 genes in the
RYGB non-omentectomy cohort compared to 11 in the RYGB
with omentectomy cohort). Most of the observed inflammatory
genes that were only decreased in the RYGB with omentectomy
cohort are reportedly associated with macrophage activation
(CH25H, CXCL2, SOCS3, LBP, NFIL3, ZFP36) [56,57,58,59,
60], consistent with the systemic decrease in MCP-1, or associated
with inflammatory events surrounding sarcopenia (ANKRD1,
LBP) [61,62]. Certain genes such as IL6 and CCL2 were
decreased in both groups at both time points relative to pre-
surgery levels, but the reductions were greater in the omentectomy
group. Changes in IL6 expression levels at 6 and 12 months in the
RYGB with omentectomy cohort were the greatest of any gene
Figure 6. Bar graph illustrating the fold change of individual genes at 6 vs. 0 months with omentectomy as determined by
microarray (grey) and TLDA profiling (black).
doi:10.1371/journal.pone.0028577.g006
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action [63,64]. IL-6 infusion reportedly increased fatty acid
oxidation in human skeletal muscle but not adipose tissue,
suggesting a role for this cytokine in stimulating skeletal muscle
lipolysis specifically [65]. In the current study, despite glucose
utilization (M) being significantly improved at both time-points,
omentectomy did not have a differential effect. Interestingly,
systemic levels of IL-6 did not change after RYGB. In contrast,
other cytokines such as CX3CR1 [66] were equally diminished at
6 and 12 months in both groups after RYGB. Circulating
monocytes with high levels of CX3CR1 (frataxylin), are present in
systemic disease, such as sepsis or HIV infection, while the
macrophage subset that invades tissues during acute localized
inflammation expresses lower levels of CX3CR1. These data
provide evidence that RYGB reduces the local inflammatory
response in muscle which is enhanced by omentectomy, and the
physiological consequences warrant further study.
The expression of several transcription factors involved in
proliferation control, (FOS, FOSB, JUNB, MYC and EGR1) was
reduced at 6 and 12 months after RYGB in both RYGB cohorts
with and without omentectomy. These five genes were among
those that showed the greatest drop in expression post-RYGB, and
their decrease was greater in the omentectomy cohort at both
time-points. FOS, FOSB and JUNB are intermediate early genes
comprising the AP-1 basic leucine zipper transcription factor
family that act on specific biological responses to regulate gene
expression. Each has been shown to be increased immediately
after exercise [35], but this study is the first to associate them with
changes in skeletal muscle after RYGB. Adipose-specific overex-
pression of DFOSB, a naturally occurring alternatively spliced
variant of FosB that is antagonistic to normal FosB-mediated gene
transcription, was recently shown to increase energy expenditure
in muscle and increase insulin sensitivity [67]. Expression of
EGR1, a GC box-binding transcription factor, has been shown to
regulate TGF-b expression which, in turn increases myostatin
expression [68]. The expression of EGR-1 was decreased over 4-
fold in the omentectomy cohorts compared to the 2- and 3-fold
reductions observed in the non-omentectomy cohort at 6 and 12
months, respectively. EGR-1 binding sites are prevalent in the
promoter binding sites for genes such as peroxisomal gamma
coactivator-1a (PGC-1a), that are important regulators of
mitochondrial biogenesis [69]. The nuclear phosphoprotein
MYC was decreased 3-fold at both 6 and 12 month time points
in the RYGB with omentectomy cohort but only 2-fold at the
same time points in the group without omentectomy. In contrast,
HOXC10, a homeoprotein associated with muscle satellite cell
activation was upregulated over 2-fold at 12 months in both
cohorts, and at 6 months in the RYGB with omentectomy group.
The protein product of this gene, together with Pax7, Asb5 and
IgSF4, was shown to be markers for skeletal muscle satellite cells
[70]. In the present study, increased HOXC10 expression at all
time points in both cohorts implies that muscle satellite cell
Figure 7. Bar graph illustrating the fold change of individual genes at 12 vs. 0 months with omentectomy as determined by
microarray (grey) and TLDA profiling (black).
doi:10.1371/journal.pone.0028577.g007
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important phenomenon in muscle remodeling, particularly after
weight loss.
Genes facilitating extracellular matrix (ECM) remodeling such
as CYR61, THBS1 and THBS4 were downregulated, consistent
with an improvement in inflammation. High levels of muscle
expression of ECM, inflammatory, and immediate early genes in
obesity could indicate a continual, unsuccessful attempt to repair
muscle damage caused by fat overload. A role for the ECM in
insulin resistance has been described but is largely unappreciated.
Infusion of FFA in subjects with normal glucose tolerance has been
shown to increase the expression of ECM genes in muscle
coincident with a decrease in insulin sensitivity [71]; furthermore,
animal studies indicate that ECM expansion contributes to insulin
resistance [72]. These studies in concert with our current results
indicate that further studies connecting obesity, the ECM, and
insulin resistance are warranted.
Three genes annotated as regulating protein turnover were
significantly altered upon RYGB in both surgical groups. The
gene encoding eEF1A2 binding protein (IGFN1 or
Dkfzp434B1231) plays a key role in protein translation, carrying
each aminoacyl-transfer RNA complex to the A site of the
ribosome after codon-anticodon recognition [73]. In cultured
myotubes, IGFN1 expression inhibited apoptosis and promoted
cell proliferation in hyper-catabolic trauma patients [74] and was
required for the muscle-specific expression of utrophin A, a
sarcomellar protein causal in the fatal neuromuscular disease
Duchenne Muscular Dystrophy [75]. In our studies IGNF1
expression was reduced greater than 4-fold, a pattern consistent
with muscle catabolism known to occur in this population. Other
genes involved in protein turnover such as FBXW10, a component
of the E3 ubiquitin ligase system that determines substrate
specificity during proteasomal degradation, demonstrated an
increased expression pattern primarily at the 12-month time
point. It seems likely that as a result of RYGB the regulation of
muscle protein maintenance is upset. Future studies in this
population examining muscle protein synthesis and muscle protein
breakdown using state-of-the-art isotopic tracer methodologies
may delineate mechanisms contributory to this observation.
At 6 and 12 months after RYGB in the non-omentectomy
group, several small nucleolar RNAs from the C/D box group
(SNORDs) were among the few genes that were upregulated in
skeletal muscle. SNORDs are a class of small RNA non-protein
coding micro RNAs that molecules that guide chemical modifi-
cation, particularly 29-O-methylation [76] and alternative splicing
[77] of other RNAs. Interestingly, the absence of small nucleolar
RNA C/D box 115 gene expression units have been implicated as
causal in Prader-Willi Syndrome [78], the most common form of
monogenetic obesity. Previous studies, however, indicate that
expression of HBII-52 is restricted to the brain [78]; thus, the
Figure 8. Correlation in fold change (log2) of gene expression as determined by Affymetrix Exon microarray and TLDA profiling. A)
6 vs. 0 months, no omentectomy, Pearson correlation coefficient rho=0.559, p,0.0001; B) 12 vs. 0 months, no omentectomy, Pearson correlation
coefficient rho=0.646, p=0.0002; C) 6 vs. 0 months, yes omentectomy, Pearson correlation coefficient rho=0.649, p=0.0002; D) 12 vs. 0 months, yes
omentectomy, Pearson correlation coefficient rho=0.640, p=0.0002.
doi:10.1371/journal.pone.0028577.g008
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muscle and the increased expression after RYGB is highly unclear.
We have identified a set of genes, which were significantly and
differentially altered after RYGB with and without omentectomy;
however, there are some important limitations to this study. First,
while the utmost effort was placed on ensuring the quality of the
muscle biopsies used for RNA extraction both before and after
surgery, it remains possible that some intercalated adipose,
adventitia and/or microvasculature may have been present in
some tissues. This phenomenon was more likely in biopsies
obtained prior to RYGB surgery, compared to those at either time
point after surgery when significant weight loss occurred, and may
lead to significant gene expression changes that are not exclusive
to skeletal muscle. For example, the observed changes in
adiponectin (ADIPOQ) and omentin-1 (ITLN1) might be
reflective of intercalated adipose tissue as this is their primary
site of production, although muscle specific expression has been
reported [79]. Thirdly, we elected to use Robust Multi-array
Averaging, a common normalization method, but did not perform
the default quantile across sample normalization method of RMA
to avoid over-correction for the small sample size. The data were
also analyzed without adjustments for multiplicity, which could
alter differential expression estimates [80]. Nevertheless, our
validation efforts focused primarily on those genes affected 4 fold
or greater (log2 – 2 fold) and, as such, any misinterpretations based
on this should be minimal. Finally, we are unable to account for
the extrinsic factors, other than those reported in Tables 1 and 2
that can affect end-organ metabolic response. As RYGB surgery is
a procedure known for its systemic and interconnected effects on
hormonal, neuronal, and biochemical impulses, the discrimination
of a muscle-specific response due solely to the removal of
omentum remains a challenge.
With regard to our overall study design, there are some
limitations that should be mentioned. The population studied was
reflective of Nashville, TN and the surrounding counties with an
ethnic distribution (Caucasians to African Americans) of 4:1. While
both the omentectomy and non-omentectomy group contained
participants with and without T2D, the proportion of subjects with
T2D was unequal between groups. There were also no Hispanics in
thestudied cohorts,basedonourgeographiclocale,and the subjects
studied were also primarily female reflective of the patient
population seeking this surgical approach; therefore, our findings
may be gender and ethnically limited.
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